Mary Moyer, MD
Family Medicine · Acoma, NMNPI 1356450043
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,755 and has fallen 98.7% since, to $22 in 2023. Among family medicine clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$565
- AstraZeneca$490
- Amgen$377
- GSK$326
- AbbVie$291
- Lilly USA, LLC$169
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,24599%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $565 |
| AstraZeneca | 32 | $490 |
| Amgen | 17 | $377 |
| GSK | 28 | $326 |
| AbbVie(2 entities) | 22 | $291 |
| Lilly USA, LLC | 13 | $169 |
| Amarin Pharma, Inc. | 5 | $159 |
| Merck | 12 | $145 |
| Pfizer | 5 | $91 |
| Boehringer Ingelheim | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Nalpropion Pharmaceuticals LLC | 3 | $45 |
| Novartis | 2 | $43 |
| Johnson & Johnson | 3 | $43 |
| Therapeuticsmd, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Eisai Inc. | 2 | $33 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Abbott | 1 | $22 |
| Exeltis, USA Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,264 in reported general payments places this provider in the 90th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 14 | $17,449 |
| DuleraMometasone/Formoterol | 11 | $3,526 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $1,149 |
| Tamsulosin Hcl | 23 | $610 |
| Atorvastatin Calcium | 33 | $398 |
| Lisinopril | 35 | $394 |
| Gabapentin | 25 | $276 |
| Metoprolol Succinate | 21 | $256 |
| Triamcinolone Acetonide | 11 | $241 |
| Losartan Potassium | 26 | $240 |
| Rosuvastatin Calcium | 21 | $221 |
| Ketoconazole | 11 | $151 |
| Levothyroxine Sodium | 17 | $141 |
| Famotidine | 11 | $139 |
| Metformin Hcl | 15 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $87 | $17,44914 claims |
| MerckDulera | $145 | $3,52611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Acoma
- Harold McFarlingFarmington$160K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
- Wendy JohnsonSanta Fe$37K
- Delliah StamppLas Cruces$21K
- Conchita PazLas Cruces$16K
- Sergio HuertaLas Cruces$11K
- Timothy GrenemyerAlbuquerque$10K
- Cheri BlackstenAlbuquerque$9K
- Brenda CuellarLas Cruces$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.